ASC Therapeutics

We are dedicated to discovering, developing and delivering cures for intractable diseases

We are passionate about helping patients lead more hopeful, healthier and happier lives

Our Focus

ASC Therapeutics is "here to cure".

ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT™ and other gene editing technologies developed after 12 years of R&D at Applied Stem Cells, Inc.

The company’s therapeutic development pipeline includes several preclinical stage programs in gene and cell therapy progressing into clinical stage in 2021 focusing on several blood disorders. 

We are devoted to find solutions for unmet medical needs and passionate about applying our new technologies to change people’s lives for the better. We hope to help patients lead healthier, more hopeful, and happier lives.

Vision

To provide cures to patients with intractable diseases through innovative technologies and therapeutics that are both groundbreaking and safe

Focus

ASC Therapeutics strives to discover, develop, and deliver gene and cell treatments to cure intractable and emerging diseases.

DNA​

Our diverse team has decades of experience in cutting edge stem-cell and gene therapy research. Together we strive to be innovators to provide platforms to revolutionize the way diseases are treated.

Our Pipeline

Hemophilia A
Gene Therapy
Hemophilia A
Gene Editing
Hemophilia B
Gene Editing
B - Thalassemia
Gene Editing
GVHD
Cell Therapy / Phase 2B
Undisclosed
Gene editing, Gene / Cell Therapy

Our current pipeline is focused on blood diseases. We are devoted to discovering, developing and delivering cures for intractable diseases using gene and cell therapies.

Not only do we have excellent teams for our in-house discovery and pre-clinical programs, we also collaborate with world renowned research institutes to enhance the power of discovery. Utilizing our cumulative experience in stem cells and gene modification technology, we are beginning to tap into neurological and immunologic diseases, as well as cancer treatments.

0
Programs

Investors & Collaborators

Hermed Capital

Hermed Capital Fund (the “Fund”) is a private equity fund that will invest primarily in healthcare industry around the world.

Fosun International

Fosun International Limited is a technology-driven consumer group that has been listed on the main board of the Hong Kong Stock Exchange (00656.HK) since 2007.​

Advantech Capital

Launched in January 2016 by Mr. Jianming Yu, Advantech Capital is a private equity fund, focused on innovation-driven growth capital in China.

Ping An Group

Ping An of China is devoted to becoming a world-leading personal financial services provider.

Stanford University

Stanford University, officially Leland Stanford Junior University, is a private research university in Stanford, California. Stanford is known for its academic achievements, wealth, close proximity to Silicon Valley, and selectivity; it ranks as one of the world's top universities.

Emory University

Emory University, a top-ranked private institution recognized internationally for its outstanding liberal arts colleges, graduate and professional schools, and one of the world's leading healthcare systems, is located on a beautiful campus in Atlanta, Georgia's historic Druid Hills neighborhood.

Shantou University

Shantou University, a key comprehensive university under the provincial Project 211 program in Guangdong, was founded in 1981 with the approval of the State Council. It is the only public university that receives funding from the Li Ka Shing Foundation.

Peking University Shenzhen Hospital

Peking University Shenzhen Hospital, opened in 1999, is a modern general hospital based in Shenzhen with an investment of RMB 4.5 billion. Under the cooperation of Shenzhen municipal government and Peking University, the hospital was absorbed into the management system of Peking University Hospital in the year 2001.

Simcere

Simcere Pharmaceutical Group is China's leading R&D-driven pharmaceutical company. It has been ranked amongst the top 100 pharmaceutical companies in China and in the top 10 of the most innovative pharmaceutical companies in China for several consecutive years. Simcere was the first Chinese biological and chemical pharmaceutical company to be listed on the New York Stock Exchange.

News

Contact us